The Australia anemia in pregnancy market is influenced by the prevalence of anemia as a significant blood disorder. Increasing research and development efforts for novel treatments and advancements in diagnostic techniques are expected to drive market growth. Iron deficiency remains a prominent cause of anemia during pregnancy. Recent findings in Australia reveal a higher incidence of pregnancy-related anemia, especially in tertiary public hospitals and with progressing gestation. These factors collectively shape the dynamics of the Australia anemia in pregnancy market.
Access Full Report @ https://www.databridgemarketresearch.com/pt/reports/australia-anemia-in-pregnancy-market
Data Bridge Market Research analyses that the Australia Anemia in Pregnancy Market tends to be around 8.8% in the forecast period of 2023-2030. The market was valued at USD 160.71 million in 2022 and would grow to USD 315.55 million by 2030. Collaborations among healthcare providers, researchers, and advocacy groups amplify awareness, enhance diagnostics, and create targeted interventions for anemia during pregnancy. This unified effort strengthens the market for effective solutions, benefiting pregnant women's health and driving market growth.
Key Findings of the Study
Well-equipped tertiary public hospitals are expected to drive the market's growth rate
Well-equipped tertiary public hospitals serve as vital pillars in identifying and addressing anemia during pregnancy. With their specialized knowledge and resources, these institutions enable accurate diagnosis and timely intervention. Their pivotal role not only ensures proper maternal care but also contributes to the growth of the Australia anemia in pregnancy market by fostering demand for effective solutions and management strategies.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Cause (Folic Acid Deficiency, Iron Deficiency, Vitamin B12 Deficiency, and Others), Treatment (Iron Products, Folic Acid Supplementation, and Others), Route of Administration (Oral, Intravenous, and Intramuscular), Prescribing Weeks (< 13 Weeks, 13-27 Weeks and ≥28 Weeks), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others)
|
|
Market Players Covered
|
Viatris Inc.(U.S.), Aspen Pharmacare Australia Pty Ltd (Australia), PharmaCare Laboratories Australia (Australia), AFT Pharmaceuticals (New Zealand), Bayer AG (Germany), A Nelson & Co Ltd (U.K.), BLACKMORES (Australia) and Care Pharma (India)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The anemia in pregnancy market is segmented on the basis of cause, treatment, route of administration, prescribing weeks, end user and distribution channel.
- On the basis of cause, the anemia in pregnancy market is segmented into folic acid deficiency, iron deficiency, vitamin b12 deficiency, and others.
- On the basis of treatment, the anemia in pregnancy market is segmented into iron products, folic acid supplementation, and others.
- On the basis of route of administration, the anemia in pregnancy market is segmented into oral, intravenous, and intramuscular.
- On the basis of prescribing weeks, the anemia in pregnancy market is segmented into < 13 weeks, 13-27 weeks and ≥28 weeks.
- On the basis of end user, the anemia in pregnancy market is segmented into hospitals, specialty clinics, home healthcare, and others.
- On the basis of distribution channel, the anemia in pregnancy market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others.
Major Players
Data Bridge Market Research recognizes the following companies as the major Australia anemia in pregnancy market players in Australia anemia in pregnancy market are Viatris Inc.(U.S.), Aspen Pharmacare Australia Pty Ltd (Australia), PharmaCare Laboratories Australia (Australia), AFT Pharmaceuticals (New Zealand), Bayer AG (Germany), A Nelson & Co Ltd (U.K.), BLACKMORES (Australia) and Care Pharma (India)
For more detailed information about the Australia anemia in pregnancy market report, click here – https://www.databridgemarketresearch.com/pt/reports/australia-anemia-in-pregnancy-market
